protein-name,gene-symbol,uniprot-id,rs-id,allele,adverse-reaction,description,pubmed-id,parent_key
Receptor tyrosine-protein kinase erbB-2,ERBB2,P04626,rs1136201,,"G Allele, heterozygote",Patients with this genotype have increased risk of cardiotoxicity with trastuzumab.,17693647,DB00072
Cytochrome P450 1A2,CYP1A2,P05177,rs762551,,C allele,Patients with this genotype have increased risk of a non-fatal myocardial infarction with caffeine,16522833,DB00201
"Glutamate receptor ionotropic, kainate 2",GRIK2,Q13002,rs2518224,,"C Allele, homozygote",Patients with this genotype have increased frequency of suicidal ideation with citalopram,17898344,DB00215
Glutamate receptor 3,GRIA3,P42263,rs4825476,,G allele,Patients with this genotype have increased frequency of suicidal ideation with citalopram,17898344,DB00215
Cyclic AMP-responsive element-binding protein 1,CREB1,P16220,rs4675690,,"T allele, homozygous",Male patients with this genotype have an increased risk of (condition: suicide) with (drug: citalopram).,17548750,DB00215
"HLA class I histocompatibility antigen, B-15 alpha chain",HLA-B,P30464,,HLA-B*15:02,HLA-B*15,The presence of this genotype in HLA-B is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis when treated with phenytoin.,25099164,DB00252
DNA polymerase subunit gamma-1,POLG,P54098,rs113994095,A467T,G > A,The presence of this polymorphism in POLG may indicate an increased risk of liver failure and death when treated with valproic acid.,,DB00313
DNA polymerase subunit gamma-1,POLG,P54098,rs113994097,W748S,G > C,The presence of this polymorphism in POLG may indicate an increased risk of liver failure and death when treated with valproic acid.,,DB00313
ATP-binding cassette sub-family G member 2,ABCG2,Q9UNQ0,rs2231142,,A allele,Patients with this genotype have an increased risk of diarrhea with gefitinib.,17148776,DB00317
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,G > A/C,Patients with this genotype have reduced metabolism of clobazam.,15483195,DB00349
Thiopurine S-methyltransferase,TPMT,P51580,rs1800462,TPMT*2,G Allele,The presence of this polymorphism in TPMT may be associated with an increased risk of developing rapid bone marrow suppression when treated with tioguanine.,21270794,DB00352
Thiopurine S-methyltransferase,TPMT,P51580,rs1800460,TPMT*3A,A Allele,The presence of this polymorphism in TPMT may be associated with an increased risk of developing rapid bone marrow suppression when treated with tioguanine.,21270794,DB00352
Thiopurine S-methyltransferase,TPMT,P51580,rs1142345,TPMT*3C,G Allele,The presence of this polymorphism in TPMT may be associated with an increased risk of developing rapid bone marrow suppression when treated with tioguanine.,21270794,DB00352
Thiopurine S-methyltransferase,TPMT,P51580,rs1800584,TPMT*4A,G > A,The presence of this polymorphism in TPMT may be associated with an increased risk of developing rapid bone marrow suppression when treated with tioguanine.,21270794,DB00352
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3,GNB3,P16520,rs5443,,TT allele,Patients with this genotype have increased weight gain with clozapine.,16141801,DB00363
HLA class I histocompatibility antigen protein P5,HCP5,Q6MZN7,rs2395029,HLA-B*5801,G allele,Patients who carry this allele are at a higher risk of experiencing severe cutaneous adverse reactions when treated with allopurinol.,23232549,DB00437
Ribonucleoside-diphosphate reductase large subunit,RRM1,P23921,rs9937,,"A allele, homozygous",Patients with this genotype have increased risk of neutropenia and neurotoxicity with gemcitabine.,17602053,DB00441
Glutathione S-transferase Mu 1,GSTM1,P09488,,GSTM1,presence of functional GSTM1,Patients with this genotype have increased risk of ototoxicity with [durg: cisplatin].,18162130,DB00515
Low-density lipoprotein receptor-related protein 2,LRP2,P98164,,,,Patients with this genotype have increased risk of ototoxicity with [durg: cisplatin].,17457342,DB00515
Glutathione S-transferase P,GSTP1,P09211,,,,Patients with this genotype have increased risk of ototoxicity with [durg: cisplatin].,18162130,DB00515
DNA repair protein complementing XP-C cells,XPC,Q01831,,,,Patients with this genotype have increased risk of ototoxicity with [durg: cisplatin].,21047201,DB00515
Thymidylate synthase,TYMS,P04818,rs34743033,TSER*2,(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3/4,Patients with this genotype have increased risk of severe neutropenia or severe diarrhea with [drug; fluorouracil].,16818689,DB00544
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801265,,C allele,Patients with this genotype have reduced metabolism of fluorouracil and increased risk of toxicity.,17848752,DB00544
Glutathione S-transferase P,GSTP1,P09211,rs1695,,A allele,Patients with this genotype have increased risk of toxicity with fluorouracil,18540691,DB00544
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs3918290,,A allele,Patients with this genotype have reduced metabolism of fluorouracil and increased risk of toxicity.,18299612,DB00544
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs67376798,,T > A,Patients with this genotype have reduced metabolism of fluorouracil and increased risk of toxicity.,23603345,DB00544
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs3918290,DPYD*2A,G > A,The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from fluorouracil therapy.,23988873,DB00544
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs55886062,DPYD*13,A > C,The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from fluorouracil therapy.,23988873,DB00544
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs67376798,,T > A,The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from fluorouracil therapy.,23988873,DB00544
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801158,DPYD*4,G > A,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from fluorouracil therapy.,23988873,DB00544
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801159,DPYD*5,A > G,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from fluorouracil therapy.,23988873,DB00544
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801160,DPYD*6,G > A,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from fluorouracil therapy.,23988873,DB00544
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801265,DPYD*9A,T > C,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from fluorouracil therapy.,23988873,DB00544
Canalicular multispecific organic anion transporter 1,ABCC2,Q92887,,ABCC2 IVS 23+56,T allele,Patients with this genotype have increased risk of toxicity with methotrexate.,18381794,DB00563
Methylenetetrahydrofolate reductase,MTHFR,P42898,rs1801133,,T allele,Patients with this genotype have increased risk of toxicity with methotrexate.,17488658,DB00563
Heat shock 70 kDa protein 1-like,HSPA1L,P34931,rs2227956,,T allele,Patients with this genotype have increased risk of cutaneous hypersensitivity reactions with carbamazepine.,16538175,DB00564
Heat shock 70 kDa protein 1A/1B,HSPA1A,P08107,rs506770,,C allele,Patients with this genotype have increased risk of cutaneous hypersensitivity reactions with carbamazepine.,16538175,DB00564
"HLA class I histocompatibility antigen, B-15 alpha chain",HLA-B,P30464,rs3130690,,T allele,Patients with this genotype have increased risk of cutaneous hypersensitivity reactions with carbamazepine.,16538176,DB00564
"HLA class I histocompatibility antigen, A-31 alpha chain",HLA-A,P16189,rs1264511,,G allele,Patients with this genotype have increased risk of cutaneous hypersensitivity reactions with carbamazepine.,16538176,DB00564
Promotilin,MLN,P12872,rs2894342,,A allele,Patients with this genotype have increased risk of cutaneous hypersensitivity reactions with carbamazepine.,16538176,DB00564
Flotillin-1,FLOT1,O75955,rs3909184,HLA-B*1502,G > C,"Taiwanese, Chinese, Indians, and Chinese–American patients with this genotype have increased risk of Stevens-Johnson syndrome or toxic epidermal necrolysis with carbamazepine.",15057820,DB00564
Mucin-21,MUC21,Q5SSG8,rs2844682,HLA-B*1502,G>A,"Taiwanese, Chinese, Indians, and Chinese–American patients with this genotype have increased risk of Stevens-Johnson syndrome or toxic epidermal necrolysis with carbamazepine.",15057820,DB00564
"HLA class I histocompatibility antigen, B-15 alpha chain",HLA-B,P30464,,HLA-B*15:02,HLA-B*15,Patients who carry this allele may be at an increased risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis when treated with carbamazepine.,23695185,DB00564
"HLA class I histocompatibility antigen, A-3 alpha chain",HLA-A,P04439,rs1061235,HLA-A*3101,A > T,Patients who carry this genotype in HLA-A are at a higher risk of experiencing a hypersensitivity reaction to carbamazepine.,21428769,DB00564
Solute carrier organic anion transporter family member 1B1,SLCO1B1,Q9Y6L6,rs4149056,SLCO1B1*5,T > C,The presence of this genotype in SLCO1B1 is associated with an increased risk of myopathy when treated with simvastatin.,24918167,DB00641
Coagulation factor V,F5,P12259,rs6025,,A allele,Patients with this genotype have increased risk of a thromboembolic event with tamoxifen.,20554945,DB00675
Cytochrome P450 1B1,CYP1B1,Q16678,rs10932125,,G allele,The presence of this genotype in CYP1B1 may be associated with an increased risk of drug-induced cytotoxicity from daunorubicin therapy.,18451141,DB00694
Heterogeneous nuclear ribonucleoprotein D0,HNRNPD,Q14103,rs3750518,,A allele,The presence of this genotype in HNRNPD may be associated with an increased risk of drug-induced cytotoxicity from daunorubicin therapy.,18451141,DB00694
SEC14-like protein 3,SEC14L3,Q9UDX4,rs6603859,,T allele,The presence of this genotype in SEC14L3 may be associated with an increased risk of drug-induced cytotoxicity from daunorubicin therapy.,18451141,DB00694
Inhibitor of nuclear factor kappa-B kinase subunit epsilon,IKBKE,Q14164,rs7929521,,A allele,The presence of this genotype in IKBKE may be associated with an increased risk of drug-induced cytotoxicity from daunorubicin therapy.,18451141,DB00694
Retinoic acid receptor gamma,RARG,P13631,rs2229774,,C>T,Pediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with daunorubicin.,27197003,DB00694
Solute carrier family 28 member 3,SLC28A3,Q9HAS3,rs7853758,,G > A,Pediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with daunorubicin.,27197003,DB00694
UDP-glucuronosyltransferase 1-6,UGT1A6,P19224,rs17863783,UGT1A6*4,G > T,Pediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with daunorubicin.,27197003,DB00694
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,681G>A,Patients with this polymorphism in CYP2C19 are poor metabolizers of clopidogrel and are associated with diminished platelet response and increased risk of adverse cardiovascular events in response to clopidogrel therapy.,23698643,DB00758
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs8175347,UGT1A1*28 or UGT1A 7/7,extra TA in promoter,The presence of this genotype in UGT1A1 may indicate an increased risk of bone marrow toxicity when treated with irinotecan.,17681105,DB00762
UDP-glucuronosyltransferase 1-7,UGT1A7,Q9HAW7,rs17868323,UGT1A7*2/*2,G allele,The presence of this genotype in UGT1A1 may indicate an increased risk of bone marrow toxicity when treated with irinotecan.,18349289,DB00762
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs10929302,UGT1A1*93,A Allele,The presence of this genotype in UGT1A1 may indicate an increased risk of bone marrow toxicity when treated with irinotecan.,17510208,DB00762
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs8175347,UGT1A1*28,"extra TA in promoter, homozygous",Patients who carry this genotype in UGT1A1 are at increased risk for neutropenia following initiation of irinotecan treatment.,26313268,DB00762
"HLA class I histocompatibility antigen, B-15 alpha chain",HLA-B,P30464,,HLA-B*15:02,HLA-B*15,Patients who carry this allele may be at an increased risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis when treated with oxcarbazepine.,,DB00776
Multidrug resistance protein 1,ABCB1,P08183,rs2032582,,T Allele (G2677T),The presence of this genotype in ABCB1 may indicate an increased risk of drug-induced neurotoxicity when treated with tacrolimus.,12352921,DB00864
Leukotriene C4 synthase,LTC4S,Q16873,rs730012,,C allele,The presence of this genotype in LTC4S may indicate an increased risk of chronic urticaria when treated with acetylsalicylic acid.,16433794,DB00945
Cytochrome P450 2C9,CYP2C9,P11712,rs1799853,CYP2C9*2,T Allele,The presence of this polymorphism in CYP2C9 is associated with reduction in phenprocoumon metabolism.,17192772,DB00946
Cytochrome P450 2C9,CYP2C9,P11712,rs1057910,CYP2C9*3,C Allele,The presence of this polymorphism in CYP2C9 is associated with reduction in phenprocoumon metabolism.,17192772,DB00946
Vitamin K epoxide reductase complex subunit 1,VKORC1,Q9BQB6,rs9934438,,G > A,The presence of this polymorphism in VKORC1 is associated with reduction in phenprocoumon metabolism.,17192772,DB00946
Cytochrome P450 2E1,CYP2E1,P05181,,CYP2E1*4,,The presence of this genotype in CYP2E1 may be associated with an increased risk of drug-induced hepatotoxicity from isoniazid treatment.,16770646,DB00951
Thiopurine S-methyltransferase,TPMT,P51580,rs1800462,TPMT*2,G Allele,Patients with this genotype have reduced metabolism of azathioprine resulting in increased toxicity.,16509759,DB00993
Thiopurine S-methyltransferase,TPMT,P51580,rs1800460,TPMT*3A,A Allele,Patients with this genotype have reduced metabolism of azathioprine resulting in increased toxicity.,16509759,DB00993
Thiopurine S-methyltransferase,TPMT,P51580,rs1142345,TPMT*3C,G Allele,Patients with this genotype have reduced metabolism of azathioprine resulting in increased toxicity.,16509759,DB00993
Retinoic acid receptor gamma,RARG,P13631,rs2229774,,C>T,Pediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with doxorubicin.,27197003,DB00997
Solute carrier family 28 member 3,SLC28A3,Q9HAS3,rs7853758,,G > A,Pediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with doxorubicin.,27197003,DB00997
UDP-glucuronosyltransferase 1-6,UGT1A6,P19224,rs17863783,UGT1A6*4,G > T,Pediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with doxorubicin.,27197003,DB00997
Thiopurine S-methyltransferase,TPMT,P51580,rs1800462,TPMT*2,G Allele,Patients with this genotype have reduced metabolism of mercaptopurine resulting in increased toxicity.,16509759,DB01033
Thiopurine S-methyltransferase,TPMT,P51580,rs1800460,TPMT*3A,A Allele,Patients with this genotype have reduced metabolism of mercaptopurine resulting in increased toxicity.,16509759,DB01033
Thiopurine S-methyltransferase,TPMT,P51580,rs1142345,TPMT*3C,G Allele,Patients with this genotype have reduced metabolism of mercaptopurine resulting in increased toxicity.,16509759,DB01033
HLA class I histocompatibility antigen protein P5,HCP5,Q6MZN7,rs2395029,HLA-B*5701,G allele,Patients who carry this SNP are at a higher risk of experiencing a hypersensitivity reaction to abacavir.,18684101,DB01048
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs3064744,UGT1A1*28,TA pair insertion,The presence of this genotype in UGT1A1 may indicate an increased risk of hyperbilirubinemia from atazanavir treatment.,26417955,DB01072
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs8175347,UGT1A1*37,TA pair insertion,The presence of this genotype in UGT1A1 may indicate an increased risk of hyperbilirubinemia from atazanavir treatment.,26417955,DB01072
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs887829,UGT1A1*80,"G > A, homozygous",The presence of this genotype in UGT1A1 may indicate an increased risk of hyperbilirubinemia from atazanavir treatment.,26417955,DB01072
Cytochrome P450 1A2,CYP1A2,P05177,rs762551,,C allele,The presence of this genotype in CYP1A2 may be associated with an increased risk of drug-related toxicity from leflunomide therapy.,18496682,DB01097
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs3918290,DPYD*2A,G > A,The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from capecitabine therapy.,23988873,DB01101
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs55886062,DPYD*13,A > C,The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from capecitabine therapy.,23988873,DB01101
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs67376798,,T > A,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from capecitabine therapy.,23988873,DB01101
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801158,DPYD*4,G > A,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from capecitabine therapy.,23988873,DB01101
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801159,DPYD*5,A > G,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from capecitabine therapy.,23988873,DB01101
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801160,DPYD*6,G > A,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from capecitabine therapy.,23988873,DB01101
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801265,DPYD*9A,T > C,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from capecitabine therapy.,23988873,DB01101
Potassium voltage-gated channel subfamily H member 2,KCNH2,Q12809,,MiRP1,KCNE2,The presence of polymorphisms in KCNH2 and KCNE2 may potentially be associated with increased susceptibility to long Q-T syndrome or cardiac arrhytmia when treated with amiodarone.,10219239,DB01118
Sodium-dependent serotonin transporter,SLC6A4,P31645,rs25531,,A allele,The presence of this polymorphism in SLC6A4 may potentially be associated with increased risk of adverse events from escitalopram.,19272758,DB01175
Cytochrome P450 2D6,CYP2D6,P10635,rs1080985,CYP2D6*2A,C > G,Patients with this genotype have reduced metabolism of metoclopramide and may be at a higher risk of experiencing adverse events.,22688145,DB01233
Cytochrome P450 2D6,CYP2D6,P10635,rs16947,CYP2D6*2,G > A,Patients with this genotype have reduced metabolism of metoclopramide and may be at a higher risk of experiencing adverse events.,22688145,DB01233
Potassium voltage-gated channel subfamily H member 2,KCNH2,Q12809,rs3815459,,G > A,The presence of this polymorphism in KCNH2 is associated with higher incidences of adverse events from metoclopramide treatment.,22688145,DB01233
Canalicular multispecific organic anion transporter 1,ABCC2,Q92887,rs12762549,,G Allele,Patients with this polymorphism in ABCC2 are at a higher risk of experiencing drug-induced leukopenia and drug-induced neutropenia when treated with docetaxel.,18294295,DB01248
"HLA class II histocompatibility antigen, DQ alpha 1 chain",HLA-DQA1,P01909,,HLA-DQA1*02:01,HLA-DQA1*02,The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.,21245432,DB01259
"HLA class II histocompatibility antigen, DRB1-11 beta chain",HLA-DRB1,P20039,,HLA-DRB1*07:01,HLA-DRB1*07,The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.,21245432,DB01259
"HLA class II histocompatibility antigen, DQ beta 1 chain",HLA-DQB1,P01920,,HLA-DQB1*02:02,HLA-DQB1*02,The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.,21245432,DB01259
Tenascin-X,TNXB,P22105,rs12153855,,T > C,The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.,21245432,DB01259
Cytochrome P450 3A4,CYP3A4,P08684,rs4646437,,G > A,Patients with metastatic renal cell carcinoma who carry this polymorphism in CYP3A4 are at a higher risk of experiencing drug-induced hypertension when treated with sunitinib.,26810136,DB01268
Vitamin K epoxide reductase complex subunit 1,VKORC1,Q9BQB6,rs9934438,,G > A,The presence of this single nucleotide polymorphism in VKORC1 is associated with reduction in acenocoumarol metabolism and increased risk of drug-related hemorrhage.,16815313,DB01418
PRKCA-binding protein,PICK1,Q9NRD5,rs713729,,T allele,The prescence of this polymorphism in PICK1 is associated with increased susceptibility to drug-related psychosis and addiction when using methamphetamine.,17606663,DB01577
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs8175347,UGT1A1*28 or UGT1A 7/7,extra TA in promoter,Patients who carry this polymorphism in UGT1A1 are at a higer risk of developing hyperbilirubinemia when treated with nilotinib.,,DB04868
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs8175347,UGT1A1*28,"extra TA in promoter, homozygous",Patients who carry this genotype in UGT1A1 are at greater risk of experiencing dose-limiting toxicity from belinostat therapy.,26313268,DB05015
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs4124874,UGT1A1*60,A > C,Patients who carry this genotype in UGT1A1 may be at greater risk of experiencing dose-limiting toxicity from belinostat therapy.,26313268,DB05015
Coagulation factor V,F5,P12259,rs6025,Factor V Leiden,A allele,Patients who carry this polymorphism in F5 are associated with an increased risk of thromboembolism when treated with eltrombopag.,,DB06210
Antithrombin-III,SERPINC1,P01008,rs121909567,,C > T,Patients who carry this polymorphism in SERPINC1 are associated with antithrombin III deficiency and an increased risk of thromboembolism when treated with eltrombopag.,27214036,DB06210
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs3064744,UGT1A1*28,TA pair insertion,The presence of this polymorphism in UGT1A1 is associated with an increase in the incidence of hyperbilirubinemia when treated with pazopanib.,20389299,DB06589
HLA class I histocompatibility antigen protein P5,HCP5,Q6MZN7,rs2395029,HLA-B*57:01,G allele,The presence of this polymorphism in HCP5 may indicate an increased risk of ALT elevation  leading to drug-related hepatotoxicty from pazpanib therapy.,26546620,DB06589
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs3918290,DPYD*2A,G > A,The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from tegafur therapy.,23988873,DB09256
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs55886062,DPYD*13,A > C,The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from tegafur therapy.,23988873,DB09256
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs67376798,,T > A,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from tegafur therapy.,23988873,DB09256
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801158,DPYD*4,G > A,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from tegafur therapy.,23988873,DB09256
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801159,DPYD*5,A > G,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from tegafur therapy.,23988873,DB09256
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801160,DPYD*6,G > A,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from tegafur therapy.,23988873,DB09256
Dihydropyrimidine dehydrogenase [NADP(+)],DPYD,Q12882,rs1801265,DPYD*9A,T > C,The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from tegafur therapy.,23988873,DB09256
